etoricoxib
Also known as Arcoxia®, MK 0663, MK-0663, 5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine, 5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl, L791456
Etoricoxib, sold under brand names including Arcoxia, Exinef and Nucoxia is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.
Chemical data
- Formula
- C18H15ClN2O2S
- Molecular weight
- 358.8 g/mol
- IUPAC name
- 5-chloro-2-(6-methyl-3-pyridinyl)-3-(4-methylsulfonylphenyl)pyridine
- SMILES
- CC1=NC=C(C=C1)C2=C(C=C(C=N2)Cl)C3=CC=C(C=C3)S(=O)(=O)C
- InChIKey
- MNJVRJDLRVPLFE-UHFFFAOYSA-N
- XLogP
- 3.3
- Polar surface area
- 68.3 Ų
- H-bond donors
- 0
- H-bond acceptors
- 4
- Formal charge
- 0
via PubChem
Research
1,012 papersArticle
6 sectionsContents
- Medical uses
- Efficacy
- Adverse effects
- Mechanism of action
- Cardiovascular safety and concerns
- References
Etoricoxib, sold under brand names including Arcoxia, Exinef and Nucoxia is a selective COX-2 inhibitor developed and commercialized by Merck. It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.
It was patented in 1996 and approved for medical use in 2002.